' An Inconvenient Truth': Add Bev or Chemo to TKIs in Lung Cancer'An Inconvenient Truth': Add Bev or Chemo to TKIs in Lung Cancer
What agents can you combine with a TKI to improve progression-free survival inEGFR-mutant lung cancer? Dr Mark Kris discusses recent data from ASCO on this topic.Medscape Oncology
Conclusion: The results of this study may provide novel biomarkers for drug resistance in NSCLC and potential therapies for overcoming drug resistance, and may also reveal the potential mechanisms underlying drug resistance in this disease.Cell Physiol Biochem 2018;51:2509 –2522
Conditions: NSCLC Stage IV; KRAS Gene Mutation; PD-1 Antibody; Chemotherapy Effect Interventions: Drug: SHR-1210; Drug: Apatinib; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Jiangsu HengRui Medicine Co., Ltd.; Shanghai Chest Hospital Not yet recruiting
Conditions: SCLC; PEG-rhG-CSF Intervention: Drug: PEG-rhG-CSF Sponsors: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.; Beijing Cancer Hospital Recruiting
Boehringer Ingelheim and the Bonnie J. Addario Lung Cancer Foundation have come together through the " Bring Hope Home for the Holidays " partnership, aimed at helping lung cancer patients.
(Burness) The CRISPR-Cas9 gene editing system may be able to restore the effectiveness of first-line chemotherapies used to treat lung cancer by deleting or 'knocking out' a gene in cancer tumors that helps the tumors develop resistance to the drugs. That was the conclusion of a new study published today in the journal Molecular Therapy Oncolytics by scientists from The Gene Editing Institute of the Helen F. Graham Cancer Center&Research Institute at Christiana Care Health System.
In conclusion, the MIR for lung cancer in different countries varies with the expenditure on health care and health system rankings.
ConclusionsTaken together, oral BPs do not increase the risk of incidence of all-cause cancer; instead, they can reduce the incidence of breast, endometrial, and upper gastrointestinal cancers among the postmenopausal OP females. Our analysis stratified by gender suggests that oral BPs may increase the incidence of liver cancer in mixed genders, while no significant association was observed in females. Careful analysis of post-marketing data should be conducted to address the clinical relevance of our results on the putative association of oral BP use and liver cancer suggested by our meta-analysis.
Jianling Liu, Meng Jiang, Zhihua Li, Xia Zhang, XiaoGang Li, Yuanyuan Hao, Xing Su, Jinglin Zhu, Chunli Zheng, Wei Xiao, Yonghua Wang
CONCLUSIONS: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high-risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. PMID: 30550346 [PubMed - as supplied by publisher]
Publication date: Available online 15 December 2018Source: Respiratory Medicine Case ReportsAuthor(s): Keigo Okamoto, Jun HanaokaAbstractCombined subsegmentectomy (CSS) is procedure as diagnostic purpose adding sufficient surgical margin. Compared to other procedure, CSS is not common, with the surgical results also being controversial. We analyzed the patients who had undergoing CSS in the right upper lobe for ground glass opacity (GGO) -dominant nodules. Between April 2011 and March 2017, we experienced 7 cases underwent CSS. In all cases, three subsegments resection and lymph node dissection using Video-Assisted Thoraci...